ITI-007 (Lumateperone Tosylate) for Schizophrenia
Sponsor: Intra-Cellular Therapies, Inc.
Terminated
ITI-007 approved by FDA
Other terminated trials from Intra-Cellular Therapies, Inc.
- Agitation in Dementia, Including Alzheimer's Disease · Phase PHASE3 · Jan 2019
- Schizophrenia · Phase PHASE1 · Dec 2014
More terminations from Intra-Cellular Therapies, Inc.
Other Schizophrenia trials with similar outcome
A PHASE2 clinical study on Schizophrenia, this trial is terminated or withdrawn. The trial is conducted by Intra-Cellular Therapies, Inc. and has accumulated 9 data snapshots since 2019. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Mar 2021 — Dec 2021 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Jan 2021 — Mar 2021 [monthly]
Suspended PHASE2
▶ Show 4 earlier versions
-
May 2020 — Jan 2021 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Nov 2019 — May 2020 [monthly]
Recruiting PHASE2
-
Apr 2019 — Nov 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Apr 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Intra-Cellular Therapies, Inc.
- New York State Psychiatric Institute
For direct contact, visit the study record on ClinicalTrials.gov .